440 related articles for article (PubMed ID: 28904745)
1. Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4
Liu Z; Chen S; Jin X; Wang Q; Yang K; Li C; Xiao Q; Hou P; Liu S; Wu S; Hou W; Xiong Y; Kong C; Zhao X; Wu L; Li C; Sun G; Guo D
Cell Biosci; 2017; 7():47. PubMed ID: 28904745
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous Knockout of CXCR4 and CCR5 Genes in CD4+ T Cells via CRISPR/Cas9 Confers Resistance to Both X4- and R5-Tropic Human Immunodeficiency Virus Type 1 Infection.
Yu S; Yao Y; Xiao H; Li J; Liu Q; Yang Y; Adah D; Lu J; Zhao S; Qin L; Chen X
Hum Gene Ther; 2018 Jan; 29(1):51-67. PubMed ID: 28599597
[TBL] [Abstract][Full Text] [Related]
3. Gene Editing of HIV-1 Co-receptors to Prevent and/or Cure Virus Infection.
Allen AG; Chung CH; Atkins A; Dampier W; Khalili K; Nonnemacher MR; Wigdahl B
Front Microbiol; 2018; 9():2940. PubMed ID: 30619107
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the editing patterns and editing efficiencies of TALEN and CRISPR-Cas9 when targeting the human CCR5 gene.
Nerys-Junior A; Braga-Dias LP; Pezzuto P; Cotta-de-Almeida V; Tanuri A
Genet Mol Biol; 2018; 41(1):167-179. PubMed ID: 29583154
[TBL] [Abstract][Full Text] [Related]
5. Genome editing of CCR5 by AsCpf1 renders CD4
Liu Z; Liang J; Chen S; Wang K; Liu X; Liu B; Xia Y; Guo M; Zhang X; Sun G; Tian G
Cell Biosci; 2020; 10():85. PubMed ID: 32670545
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9.
Li C; Guan X; Du T; Jin W; Wu B; Liu Y; Wang P; Hu B; Griffin GE; Shattock RJ; Hu Q
J Gen Virol; 2015 Aug; 96(8):2381-2393. PubMed ID: 25854553
[TBL] [Abstract][Full Text] [Related]
7. CCR5 editing by Staphylococcus aureus Cas9 in human primary CD4
Xiao Q; Chen S; Wang Q; Liu Z; Liu S; Deng H; Hou W; Wu D; Xiong Y; Li J; Guo D
Retrovirology; 2019 Jun; 16(1):15. PubMed ID: 31186067
[TBL] [Abstract][Full Text] [Related]
8. Disruption of HIV-1 co-receptors CCR5 and CXCR4 in primary human T cells and hematopoietic stem and progenitor cells using base editing.
Knipping F; Newby GA; Eide CR; McElroy AN; Nielsen SC; Smith K; Fang Y; Cornu TI; Costa C; Gutierrez-Guerrero A; Bingea SP; Feser CJ; Steinbeck B; Hippen KL; Blazar BR; McCaffrey A; Mussolino C; Verhoeyen E; Tolar J; Liu DR; Osborn MJ
Mol Ther; 2022 Jan; 30(1):130-144. PubMed ID: 34737067
[TBL] [Abstract][Full Text] [Related]
9. CRISPR-Cas9-mediated gene disruption of HIV-1 co-receptors confers broad resistance to infection in human T cells and humanized mice.
Li S; Holguin L; Burnett JC
Mol Ther Methods Clin Dev; 2022 Mar; 24():321-331. PubMed ID: 35229006
[TBL] [Abstract][Full Text] [Related]
10. Genome modification of CXCR4 by Staphylococcus aureus Cas9 renders cells resistance to HIV-1 infection.
Wang Q; Chen S; Xiao Q; Liu Z; Liu S; Hou P; Zhou L; Hou W; Ho W; Li C; Wu L; Guo D
Retrovirology; 2017 Nov; 14(1):51. PubMed ID: 29141633
[TBL] [Abstract][Full Text] [Related]
11. CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection.
Wang W; Ye C; Liu J; Zhang D; Kimata JT; Zhou P
PLoS One; 2014; 9(12):e115987. PubMed ID: 25541967
[TBL] [Abstract][Full Text] [Related]
12. Closing the Door with CRISPR: Genome Editing of CCR5 and CXCR4 as a Potential Curative Solution for HIV.
Freen-van Heeren JJ
BioTech (Basel); 2022 Jul; 11(3):. PubMed ID: 35892930
[TBL] [Abstract][Full Text] [Related]
13. Combination gene therapy for HIV using a conditional suicidal gene with CCR5 knockout.
Mehmetoglu-Gurbuz T; Yeh R; Garg H; Joshi A
Virol J; 2021 Jan; 18(1):31. PubMed ID: 33516234
[TBL] [Abstract][Full Text] [Related]
14. Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection.
Hou P; Chen S; Wang S; Yu X; Chen Y; Jiang M; Zhuang K; Ho W; Hou W; Huang J; Guo D
Sci Rep; 2015 Oct; 5():15577. PubMed ID: 26481100
[TBL] [Abstract][Full Text] [Related]
15. CCR5 Disruption in Induced Pluripotent Stem Cells Using CRISPR/Cas9 Provides Selective Resistance of Immune Cells to CCR5-tropic HIV-1 Virus.
Kang H; Minder P; Park MA; Mesquitta WT; Torbett BE; Slukvin II
Mol Ther Nucleic Acids; 2015 Dec; 4():e268. PubMed ID: 26670276
[TBL] [Abstract][Full Text] [Related]
16. [Deep lung--cellular reaction to HIV].
Tavares Marques MA; Alves V; Duque V; Botelho MF
Rev Port Pneumol; 2007; 13(2):175-212. PubMed ID: 17492233
[TBL] [Abstract][Full Text] [Related]
17. Inducing CCR5Δ32/Δ32 Homozygotes in the Human Jurkat CD4+ Cell Line and Primary CD4+ Cells by CRISPR-Cas9 Genome-Editing Technology.
Qi C; Li D; Jiang X; Jia X; Lu L; Wang Y; Sun J; Shao Y; Wei M
Mol Ther Nucleic Acids; 2018 Sep; 12():267-274. PubMed ID: 30195765
[TBL] [Abstract][Full Text] [Related]
18. Temperature effect on CRISPR-Cas9 mediated genome editing.
Xiang G; Zhang X; An C; Cheng C; Wang H
J Genet Genomics; 2017 Apr; 44(4):199-205. PubMed ID: 28412228
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of Latent HIV-1 Proviral DNA Using Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 Treatment and the Assessment of Off-Target Effects.
Xu Y; Peng X; Zheng Y; Jin C; Lu X; Han D; Fu H; Chen C; Wu N
Front Microbiol; 2021; 12():629153. PubMed ID: 34122355
[TBL] [Abstract][Full Text] [Related]
20. CRISPR-Cas9 system: A new-fangled dawn in gene editing.
Gupta D; Bhattacharjee O; Mandal D; Sen MK; Dey D; Dasgupta A; Kazi TA; Gupta R; Sinharoy S; Acharya K; Chattopadhyay D; Ravichandiran V; Roy S; Ghosh D
Life Sci; 2019 Sep; 232():116636. PubMed ID: 31295471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
